![[Matthew Mobergs avatar]](https://franklintempletonprod.widen.net/content/gmthnin2t2/webp/Moberg_Matthew_500x500.png){kind=avatar}
Managed Fund Since 2020
Equity Active
HELX Franklin Genomic Advancements ETF
- Forefront of genomic innovation. Invests in companies that are driving advancements in DNA sequencing, gene editing and personalized medicine, paving the way for groundbreaking health care solutions.
- Research-driven. Uses bottom-up fundamental analysis conducted by a dedicated, industry-specific team to identify disruptive business models at the right stage for investment.
- Innovation expertise. Actively managed by a seasoned portfolio management team that is based in Silicon Valley.
Popular Documents
Overview
Fund Facts
Fund description
The fund seeks capital appreciation by investing in equity securities inside and outside of the United States, including developing or emerging markets. The fund invests in companies that are relevant to its investment theme of genomic advancements that the investment manager believes are substantially focused on/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business.
- Benchmark
- Russell 3000 Index
- Fund Inception Date
- 02/25/2020
- Listing Exchange
- Cboe
Identifiers
- Ticker
- HELX
- CUSIP Code
- 35473P520
- ISIN Code
- US35473P5200
- Bloomberg Code
- HELX US
Average Annual Total Returns As of 02/28/2026
- 18.47%1 Year
- 5.24%3 Years
- -5.05%5 Years
- —10 Years
- 5.66%Since Inception
02/25/2020
Performance data quoted represents past performance, which does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the figures shown.
Top Sectors
As of 03/31/2026 % of Total (Updated Daily)
Biotechnology54.30% | |
Life Sciences Tools & Services17.63% | |
Pharmaceuticals11.26% | |
Health Care Services7.36% | |
Other2.97% |
Additional Fund Info
- Fiscal Year End
- March 31
- ETF Type
- Active
- Morningstar Category
5 - Health
Trading Characteristics
- Shares Outstanding
- 650,000
- Daily Volume
- 1,635
- 20-Day Average Volume
- 1357.61
Manager and Commentary
About the Team
Franklin Equity understands innovation from every angle—our decades of experience investing in complex change fuels a differentiated perspective on how public and private companies accelerate growth and unlock value. Leveraging fundamental depth and quantitative precision, we identify catalysts for transformation that reshape companies and industries. Our expertise, spanning from growth to value, brings together diverse perspectives that help us spot opportunities ahead of the market.
Franklin Equity
Latest Insights
February 18, 2026
February 16, 2026
February 9, 2026
Performance
Calendar Year Returns
As of 02/28/2026
Performance data quoted represents past performance, which does not guarantee future results. Current performance may be lower or higher than the figures shown. Principal value and investment returns will fluctuate, and investors' shares, when redeemed, may be worth more or less than the original cost. Returns are based on Market Price or NAV, assume the reinvestment of all distributions and the deduction of all Fund expenses. Performance would have been lower if expenses had not been waived in various periods. Returns for periods of less than one year are not annualized.
Franklin Genomic Advancements ETF - Market Price Return (%)
Franklin Genomic Advancements ETF - NAV Return (%)
Russell 3000 Index (%)
Ratings 6
©2025 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Portfolio
Assets
As of03/31/2026 (Updated Daily)
- Total Net Assets
- $21.45 Million
Positions
As of 03/30/2026 (Updated Daily)
Number of Holdings
- Fund
- 61
Portfolio Statistics
As of 03/30/2026 (Updated Daily)
Weighted Average Market Capitalization (USD)
- Fund
- $57.15 Billion
Geographic Allocation
As of 03/30/2026 % of Total (Updated Daily)
| Geography | Fund | Benchmark |
|---|---|---|
North America | 83.58% | 99.30% |
| United States | 83.58% | 99.12% |
Europe | 9.45% | 0.35% |
| United Kingdom | 3.49% | 0.12% |
| Germany | 2.78% | 0.00% |
| Netherlands | 2.18% | 0.01% |
| Switzerland | 1.01% | 0.02% |
Asia | 3.77% | 0.09% |
| South Korea | 3.77% | 0.04% |
Cash & Cash Equivalents | 3.19% | — |
| Cash & Cash Equivalents | 3.19% | — |
Holdings
As of 03/31/2026 (Updated Daily)
GUARDANT HEALTH INC
NATERA INC
KRYSTAL BIOTECH INC
UNITED THERAPEUTICS CORP
INSMED INC
BRIDGEBIO PHARMA INC
LIGAND PHARMACEUTICALS
ASTRAZENECA PLC
ADAPTIVE BIOTECHNOLOGIES
CASH
Distributions & Tax
- Distribution Frequency
- AnnuallyThis fund is an ex-Dividend fund
- Capital Gain Distributions
- December
Distributions are not guaranteed and are subject to change.
Final composition of the current year’s distribution—income, capital gains and/or return of capital—are based on US tax rules and will be determined by February of the following year. For tax characterization of a distribution, such as return of capital and tax-exempt income, click on the “Tax Information” tab above.
Distributions Per Share
12/31/2025
Annually, a fund must distribute all realized capital gains net of realized losses, so the fund will not be subject to an entity level income tax. A fund’s capital gain distribution in a particular year may be a result of the disposition of holdings that appreciated in value during prior years. Thus, while the fund may gain or lose value over the course of a year, a capital gain distribution paid by the fund may not be indicative of current performance of the fund.
The distributable amount of net capital gains are paid on a per-share basis to all investors who hold shares of the fund on the record date of the distribution and are recognized by the shareholder for tax purposes as of the ex-date of the distribution, regardless of when the gains or losses arose in the fund. Net gains on holdings held long term by the fund would be distributed to shareholders as a long-term capital gain distribution no matter how long the shareholder has owned shares in the fund.
Refer to the fund’s annual report or statement of additional information for specific information regarding distributions.
Pricing
Pricing History
As of 03/31/2026 (Updated Daily)
Daily Fund Prices
As of 03/31/2026
Share Prices
As of 03/31/2026
52-Week Range
- Highest NAV
As of 11/28/2025 - $38.07
- Lowest NAV
As of 04/08/2025 - $24.08
- Highest Market Price
As of 01/22/2026 - $38.10
- Lowest Market Price
As of 04/08/2025 - $23.96
Documents
Fund Literature
| Name | Download | Add to Cart | |
|---|---|---|---|
| Factsheet - Franklin Genomic Advancements ETF |
Regulatory Documents
| Name | Download | Add to Cart | |
|---|---|---|---|
| Annual Report - Franklin Genomic Advancements ETF - Single Class | |||
| Annual Financial Statements and Other Information - Franklin Templeton ETF Trust 2 | |||
| Semi-Annual Report - Franklin Genomic Advancements ETF - Single Class | |||
| Semi-Annual Financial Statements and Other Information - Franklin Income Equity Focus ETF | |||
| Prospectus - Franklin Templeton ETF Trust 2 Active Funds | |||
| Summary Prospectus - Franklin Genomic Advancements ETF | |||
| Statement of Additional Information - Franklin Templeton ETF Trust 2 Active Funds | |||
| Fiscal Q1 Holdings - Franklin Templeton ETF Trust Smart Beta Funds | |||
| Q3 Portfolio Holdings - Franklin Templeton ETF Trust |
Risks
All investments involve risks, including possible loss of principal. Equity securities are subject to price fluctuation and possible loss of principal. The fund’s investment strategies incorporate the identification of thematic investment opportunities, and its performance may be negatively impacted if the investment manager does not correctly identify such opportunities or if the theme develops in an unexpected manner. By focusing its investments in health care-related industries, the fund carries much greater risks of adverse developments and price movements in such industries than a fund that invests in a wider variety of industries. International investments are subject to special risks, including currency fluctuations and social, economic and political uncertainties, which could increase volatility. These risks are magnified in emerging markets. The portfolio is non-diversified and may invest in a relatively small number of issuers, which may negatively impact the fund's performance and result in greater fluctuation in the value of the fund's shares. The manager may consider environmental, social and governance (ESG) criteria in the research or investment process; however, ESG considerations may not be a determinative factor in security selection. In addition, the manager may not assess every investment for ESG criteria, and not every ESG factor may be identified or evaluated. When the fund’s size is small, the fund may experience low trading volume and wide bid/ask spreads. These and other risks are discussed in the fund’s prospectus.
Important Information
Total Returns include change in share price, assume reinvestment of all distributions, and reflect the deduction of fund expenses and applicable fees. Total returns, distribution rate, and yields reflect any applicable expense reductions and fee waivers; without these reductions, the results would have been lower.
Certain share classes are only offered to eligible investors as stated in the prospectus. Different minimums may apply to clients of certain service agents. All classes of shares are not available through all distribution channels. See the Fund's prospectus for additional information.
Most funds offer multiple share classes. Share classes are subject to different fees and expenses, which will affect their performance.
Franklin Distributors, LLC. Member FINRA, SIPC. All entities mentioned are Franklin Templeton affiliated companies. Investment Products: NOT FDIC INSURED | NO BANK GUARANTEE | MAY LOSE VALUE.
Reports and other information about the funds are available on the EDGAR Database on the SEC's Internet site at www.sec.gov.
You need Adobe Acrobat Reader to view and print PDF documents. Download a free version from Adobe's website.
Important data provider notices and terms available at www.franklintempletondatasources.com.
Performance data quoted represents past performance, which does not guarantee future results.
CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.
Indexes are unmanaged and one cannot invest directly in an index. They do not reflect any fees, expenses or sales charges.
Investors should carefully consider a fund's investment goals, risks, sales charges and expenses before investing. The prospectus contains this and other information. Please read the prospectus carefully before investing or sending money.
The Russell 3000 Index measures the performance of the 3,000 largest U.S. companies based on total market capitalization.
Source: FTSE.